Leerink Partnrs Analysts Lower Earnings Estimates for BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) - Leerink Partnrs reduced their FY2025 EPS estimates for shares of BioMarin Pharmaceutical in a research note issued on Tuesday, April 16th. Leerink Partnrs analyst J. Schwartz now expects that the biotechnology company will earn $1.98 per share for the year, down from their prior estimate of $2.16. The consensus estimate for BioMarin Pharmaceutical's current full-year earnings is $1.85 per share. Leerink Partnrs also issued estimates for BioMarin Pharmaceutical's FY2026 earnings at $2.37 EPS.

Other analysts also recently issued research reports about the company. Royal Bank of Canada restated a "sector perform" rating and set a $100.00 price objective on shares of BioMarin Pharmaceutical in a report on Friday, February 23rd. Cantor Fitzgerald restated an "overweight" rating and set a $100.00 price objective on shares of BioMarin Pharmaceutical in a report on Friday, February 23rd. Piper Sandler cut their price objective on BioMarin Pharmaceutical from $115.00 to $107.00 and set an "overweight" rating on the stock in a report on Friday, February 23rd. Canaccord Genuity Group restated a "hold" rating and set a $91.00 price objective on shares of BioMarin Pharmaceutical in a report on Thursday, February 29th. Finally, Stifel Nicolaus restated a "buy" rating and set a $101.00 price objective on shares of BioMarin Pharmaceutical in a report on Thursday, December 21st. Seven research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $107.61.

BioMarin Pharmaceutical Price Performance

NASDAQ BMRN traded down $0.40 on Thursday, reaching $90.07. The company's stock had a trading volume of 944,850 shares, compared to its average volume of 1,348,617. The firm's 50 day moving average is $87.57 and its two-hundred day moving average is $89.11. The company has a debt-to-equity ratio of 0.12, a quick ratio of 1.57 and a current ratio of 2.51. The stock has a market cap of $17.00 billion, a PE ratio of 102.35, a PEG ratio of 1.68 and a beta of 0.31. BioMarin Pharmaceutical has a twelve month low of $76.02 and a twelve month high of $99.56.

BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report) last issued its quarterly earnings results on Thursday, February 22nd. The biotechnology company reported $0.49 earnings per share for the quarter, beating analysts' consensus estimates of $0.44 by $0.05. BioMarin Pharmaceutical had a net margin of 6.93% and a return on equity of 5.01%. The company had revenue of $646.21 million during the quarter, compared to the consensus estimate of $639.53 million. During the same period in the prior year, the company earned $0.11 EPS. BioMarin Pharmaceutical's revenue was up 20.2% on a year-over-year basis.

Insider Activity at BioMarin Pharmaceutical

In related news, CAO Erin Burkhart sold 2,286 shares of the firm's stock in a transaction that occurred on Wednesday, April 10th. The shares were sold at an average price of $90.00, for a total transaction of $205,740.00. Following the transaction, the chief accounting officer now owns 16,156 shares of the company's stock, valued at $1,454,040. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other BioMarin Pharmaceutical news, CAO Erin Burkhart sold 2,286 shares of the stock in a transaction that occurred on Wednesday, April 10th. The stock was sold at an average price of $90.00, for a total transaction of $205,740.00. Following the transaction, the chief accounting officer now owns 16,156 shares in the company, valued at $1,454,040. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Jean Jacques Bienaime sold 1,000 shares of the stock in a transaction that occurred on Tuesday, February 27th. The shares were sold at an average price of $90.35, for a total value of $90,350.00. Following the transaction, the director now owns 562,203 shares in the company, valued at approximately $50,795,041.05. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 103,229 shares of company stock valued at $9,062,967. 1.84% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On BioMarin Pharmaceutical

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Stratos Wealth Partners LTD. grew its holdings in BioMarin Pharmaceutical by 2.1% during the fourth quarter. Stratos Wealth Partners LTD. now owns 5,709 shares of the biotechnology company's stock valued at $550,000 after purchasing an additional 115 shares during the last quarter. CWM LLC grew its stake in shares of BioMarin Pharmaceutical by 10.0% in the third quarter. CWM LLC now owns 1,301 shares of the biotechnology company's stock worth $115,000 after acquiring an additional 118 shares during the last quarter. KB Financial Partners LLC grew its stake in shares of BioMarin Pharmaceutical by 51.3% in the third quarter. KB Financial Partners LLC now owns 348 shares of the biotechnology company's stock worth $31,000 after acquiring an additional 118 shares during the last quarter. Virtus ETF Advisers LLC grew its stake in shares of BioMarin Pharmaceutical by 3.8% in the fourth quarter. Virtus ETF Advisers LLC now owns 3,342 shares of the biotechnology company's stock worth $322,000 after acquiring an additional 121 shares during the last quarter. Finally, Howe & Rusling Inc. grew its stake in shares of BioMarin Pharmaceutical by 0.4% in the fourth quarter. Howe & Rusling Inc. now owns 36,279 shares of the biotechnology company's stock worth $3,755,000 after acquiring an additional 128 shares during the last quarter. Institutional investors and hedge funds own 98.71% of the company's stock.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.